6533b862fe1ef96bd12c6e0c

RESEARCH PRODUCT

Use of gabapentin to reduce chronic neuropathic pain in Fabry disease.

Markus RiesEugen MengelK. S. KimMathias BeckF. KrummenauerG. KutschkeF. Birklein

subject

AdultMalemedicine.medical_specialtyDiabetic neuropathyGabapentinAdolescentCyclohexanecarboxylic Acidsmedicine.medical_treatmentAcetatesGeneticsmedicineHumansBrief Pain InventoryAminesGenetics (clinical)gamma-Aminobutyric AcidPain Measurementbusiness.industryVascular diseaseEnzyme replacement therapymedicine.diseaseFabry diseaseSurgeryAnticonvulsantTreatment OutcomeAnesthesiaNeuropathic painFabry DiseaseNeuralgiaAnticonvulsantsGabapentinbusinessmedicine.drug

description

The effect of the anticonvulsant gabapentin on neuropathic pain was studied in six male patients with Fabry disease, aged 15-45 years. After 4 weeks of treatment, pain, as measured using the Brief Pain Inventory, was decreased compared with baseline. Treatment was generally well tolerated. This study indicates that gabapentin should be considered as a treatment option for the neuropathic pain of Fabry disease.

yearjournalcountryeditionlanguage
2003-09-16Journal of inherited metabolic disease
10.1023/a:1025127723729https://pubmed.ncbi.nlm.nih.gov/12971431